نتایج جستجو برای: لنفوسیتهای نفوذ یافته درون تومور til

تعداد نتایج: 188593  

Journal: :Journal of immunology 2005
Mythili Koneru David Schaer Ngozi Monu Aidee Ayala Alan B Frey

CD8+ tumor-infiltrating lymphocytes (TIL) are severely deficient in cytolysis, a defect that may permit tumor escape from immune-mediated destruction. Because lytic function is dependent upon TCR signaling, we have tested the hypothesis that primary TIL have defective signaling by analysis of the localization and activation status of TIL proteins important in TCR-mediated signaling. Upon conjug...

2014
Troels Holz Borch Rikke Andersen Per Kongsted Özcan Met Mads Hald Andersen Per thor Straten Marco Donia Inge Marie Svane

Background Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has proven to be a powerful treatment option for patients with metastatic melanoma, even when heavily pretreated, with response rates of approximately 50% and durable complete responses in about 15%. However, there is still a need for improving TIL efficacy and a promising strategy is combination with immunomodul...

2015
Sanja Stevanović Pasetto Anna Jared J Gartner Eric Tran Paul F Robbins Steven A Rosenberg Christian S Hinrichs

Background Adoptive transfer of tumor-infiltrating lymphocytes (TIL) can mediate complete regression of metastatic cervical cancer, but the immunological landscape of the anti-tumor T cell responses in these patients is not fully understood. Reactivity against the human papillomavirus (HPV)-derived antigens may contribute to the clinical responses, but whether other immunogenic tumor antigens a...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2000
A T Stopeck A Gessner T P Miller E M Hersh C S Johnson H Cui Y Frutiger T M Grogan

Tumor-infiltrating CD8+ T-lymphocytes (T-TILs) are thought to be relevant to immunosurveillance of several tumor types including B-cell non-Hodgkin's lymphoma. B- and T-lymphocyte interactions via cellular adhesion molecules (CAMs), recognition molecules (HLAs), and costimulatory molecules (CSMs) are necessary for optimal antigen-specific T-cell activation to occur and may be important in gener...

2013
Jessica Ann Chacon Richard C. Wu Pariya Sukhumalchandra Jeffrey J. Molldrem Amod Sarnaik Shari Pilon-Thomas Jeffrey Weber Patrick Hwu Laszlo Radvanyi

Adoptive T-cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) can induce tumor regression in up to 50% or more of patients with unresectable metastatic melanoma. However, current methods to expand melanoma TIL, especially the "rapid expansion protocol" (REP) were not designed to enhance the generation of optimal effector-memory CD8(+) T cells for infusion. One approach to this proble...

2011
Shu-Fang Wang Stéphane Fouquet Maxime Chapon Hélène Salmon Fabienne Regnier Karine Labroquère Cécile Badoual Diane Damotte Pierre Validire Eve Maubec Nicolas B. Delongchamps Aurélie Cazes Laure Gibault Marylène Garcette Marie-Caroline Dieu-Nosjean Marc Zerbib Marie-Françoise Avril Armelle Prévost-Blondel Clotilde Randriamampita Alain Trautmann Nadège Bercovici

To improve cancer immunotherapy, a better understanding of the weak efficiency of tumor-infiltrating T lymphocytes (TIL) is necessary. We have analyzed the functional state of human TIL immediately after resection of three types of tumors (NSCLC, melanoma and RCC). Several signalling pathways (calcium, phosphorylation of ERK and Akt) and cytokine secretion are affected to different extents in T...

Journal: :Journal of immunology 2001
S Radoja M Saio A B Frey

Induction of Fas-mediated activation-induced cell death in antitumor T cells has been hypothesized to permit tumor escape from immune destruction. Several laboratories have proposed that expression of Fas ligand (L) by tumor is the basis for this form of T cell tolerance. In this study, we characterized murine tumor-infiltrating lymphocytes (TIL) for activation status, cell cycle status, level ...

2017
Sivan Seliktar-Ofir Efrat Merhavi-Shoham Orit Itzhaki Sharon Yunger Gal Markel Jacob Schachter Michal J. Besser

Adoptive cell therapy (ACT) of autologous tumor infiltrating lymphocytes (TIL) is an effective immunotherapy for patients with solid tumors, yielding objective response rates of around 40% in refractory patients with metastatic melanoma. Most clinical centers utilize bulk, randomly isolated TIL from the tumor tissue for ex vivo expansion and infusion. Only a minor fraction of the administered T...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2017
A-S Hamy J-Y Pierga A Sabaila E Laas H Bonsang-Kitzis C Laurent A Vincent-Salomon P Cottu F Lerebours R Rouzier M Lae F Reyal

Background The role of tumor-infiltrating lymphocytes (TILs) in breast cancer has been extensively studied over the last decade. High TILs levels have been associated with pathological response rate in the neoadjuvant setting and with better outcomes in the adjuvant setting. However, little attention has been paid to changes in TILs and residual TIL levels after neoadjuvant chemotherapy (NAC). ...

Journal: :Journal of immunotherapy 2014
Marie-Andrée Forget Shruti Malu Hui Liu Christopher Toth Sourindra Maiti Charuta Kale Cara Haymaker Chantale Bernatchez Helen Huls Ena Wang Francesco M Marincola Patrick Hwu Laurence J N Cooper Laszlo G Radvanyi

PURPOSE Adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL) is a therapy for metastatic melanoma with response rates of up to 50%. However, the generation of the TIL transfer product is challenging, requiring pooled allogeneic normal donor peripheral blood mononuclear cells (PBMC) used in vitro as "feeders" to support a rapid-expansion protocol. Here, we optimized a platf...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید